Regulatory network involving miRNAs and genes in serous ovarian carcinoma
- Authors:
- Haiyan Zhao
- Hao Xu
- Luchen Xue
-
Affiliations: College of Computer Science and Technology, Jilin University, Changchun, Jilin 130012, P.R. China, College of Software, Jilin University, Changchun, Jilin 130012, P.R. China - Published online on: September 14, 2017 https://doi.org/10.3892/ol.2017.6927
- Pages: 6259-6268
This article is mentioned in:
Abstract
 |
 |
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW and Kim S: microRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Singer G, Kurman RJ, Chang HW, Cho SK and Shih IeM: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 160:1223–1228. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Soussi T and Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 1:233–240. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Z, Kim J, He L, Creighton CJ, Gunaratne PH, Hawkins SM and Matzuk MM: Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. Biol Reprod. 91:1132014. View Article : Google Scholar : PubMed/NCBI | |
|
Hobert O: Gene regulation by transcription factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Polakis P: Wnt signaling and cancer. Genes Dev. 4:1837–1851. 2000. | |
|
Tran DH, Satou K, Ho TB and Pham TH: Computational discovery of miR-TF regulatory modules in human genome. Bioinformation. 4:371–377. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA and Croce CM: microRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ambros V: microRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Li J, Ding X, He M and Cheng SY: microRNA and cancer. AAPS J. 2:309–317. 2010. View Article : Google Scholar | |
|
Gao X, Qiao Y, Han D, Zhang Y and Ma N: Enemy or partner: Relationship between intronic micrornas and their host genes. IUBMB Life. 64:835–840. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez A, Griffiths-Jones S, Ashurst JL and Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res. 14:1902–1910. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Baskerville S and Bartel DP: Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA. 11:241–247. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cao G, Huang B, Liu Z, Zhang J, Xu H, Xia W, Li J, Li S, Chen L, Ding H, et al: Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun. 396:978–982. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P and Hatzigeorgiou AG: The database of experimentally supported targets: A functional update of TarBase. Nucleic Acids Res. 37:(Database Issue). D155–D158. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al: miRTarBase update 2014: An information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 42:(Database Issue). D78–D85. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li T: miRecords: An integrated resource for microRNA-target interactions. Nucleic Acids Res. 37:(Database Issue). D105–D110. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kozomara A and Griffiths-Jones S: miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:(Database Issue). D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G and Liu Y: miR2Disease: A manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 37:(Database Issue). D98–D104. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, et al: Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 128:506–511. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Singer G, Kurman RJ, Chang HW, Cho SK and Shih IeM: Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 160:1223–1228. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Schmid S, Bieber M, Zhang F, Zhang M, He B, Jablons D and Teng NN: Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer. 21:975–980. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS and Mok SC: Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol. 119:114–120. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM and Mes-Masson AM: Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer. 119:599–607. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Thériault BL, Cybulska P, Shaw PA, Gallie BL and Bernardini MQ: The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells. J Ovarian Res. 7:1232014. View Article : Google Scholar : PubMed/NCBI | |
|
Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR and Hahn WC: The tyrosine kinase adaptor protein FRS2 is oncogenic and amplified in high-grade serous ovarian cancer. Mol Cancer Res. 13:502–509. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Sun J and Zhao Z: Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer. Mol Biosyst. 9:3187–3198. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xiangjun He, Jing Yang, Qi Zhang, Heng Cui and Yujun Zhang: Shortening of the 3′untranslated region: An important mechanism leading to overexpression of HMGA2 in serous ovarian cancer. Chin Med J. 127:494–499. 2014.PubMed/NCBI | |
|
Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM and Mes-Masson AM: SET complex in serous epithelial ovarian cancer. Int J Cancer. 119:2119–2126. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon JY, Seo YR and Ahn WS: Recognition of potential predictive markers for diagnosis in Korean serous ovarian cancer patients at stage IIIc using array comparative genomic hybridization with high resolution. Mol Cell Toxicol. 7:772011. View Article : Google Scholar | |
|
Bi FF, Li D and Yang Q: Promoter hypomethylation, especially around the E26 transformation-specific motif and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. BMC Cancer. 13:902013. View Article : Google Scholar : PubMed/NCBI | |
|
Dai W, Zeller C, Masrour N, Siddiqui N, Paul J and Brown R: Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clin Cancer Res. 19:5788–5797. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, et al: Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol. 124:582–588. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Amankwah EK, Wang Q, Schildkraut JM, Tsai YY, Ramus SJ, Fridley BL, Beesley J, Johnatty SE, Webb PM, Chenevix-Trench G, et al: Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: A report from the ovarian cancer association consortium. PLoS One. 6:e196422011. View Article : Google Scholar : PubMed/NCBI | |
|
Kashuba V, Dmitriev AA, Krasnov GS, Pavlova T, Ignatjev I, Gordiyuk VV, Gerashchenko AV, Braga EA, Yenamandra SP, Lerman M, et al: NotI microarrays: Novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer. Int J Mol Sci. 13:13352–13377. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kurita T, Izumi H, Kagami S, Kawagoe T, Toki N, Matsuura Y, Hachisuga T and Kohno K: Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer. Cancer Sci. 103:239–244. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, et al: Microarray analysis of early stage serous ovarian cancers demonstrates profiles predictive of favorable outcome. Clin Cancer Res. 15:2448–2455. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hjerpe E, Brage SE, Stolt Frostvik M, Johansson H, Shoshan M and Avall-Lundqvist E: Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites. Int J Gynecol Cancer. 24:1389–1394. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, et al: LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 72:4060–4073. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tanwar PS, Mohapatra G, Chiang S, Engler DA, Zhang L, Kaneko-Tarui T, Ohguchi Y, Birrer MJ and Teixeira JM: Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis. 35:546–553. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tamir A, Jag U, Sarojini S, Schindewolf C, Tanaka T, Gharbaran R, Patel H, Sood A, Hu W, Patwa R, et al: Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. J Ovarian Res. 7:1092014. View Article : Google Scholar : PubMed/NCBI | |
|
He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang Y, Li SX, Li Y, Zhu HT and Duan T: Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem. 33:173–184. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, et al: Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res. 23:7667–7673. 2008. View Article : Google Scholar | |
|
Li YL, Ye F, Hu Y, Lu WG and Xie X: Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal Biochem. 394:110–116. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li YL, Ye F, Cheng XD, Hu Y, Zhou CY, Lü WG and Xie X: Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. Eur J Cancer. 46:2104–2118. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Borley J, Ghaem-Maghami S, Honeyfield L, Williamson R and Brown R: Hypomethylation of MSX1 is associated with decreased gene expression, poor progression free survival and chemotherapy resistance in serous ovarian cancer. An Int J Obstetr Gynaecol. 120:2492013. | |
|
Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN and Nie G: HtrA3 is downregulated in cancer cell lines and significantly reduced in primary serous and granulosa cell ovarian tumors. J Cancer. 4:152–164. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kumtepe Y, Halici Z, Sengul O, Kunak CS, Bayir Y, Kilic N, Cadirci E, Pulur A and Bayraktutan Z: High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker. Eur J Med Res. 18:182013. View Article : Google Scholar : PubMed/NCBI | |
|
Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR and Berchuck A: High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol. 96:355–361. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, et al: Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res. 20:6618–6630. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, et al: Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 100:1421–1428. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Z, Kim J, He L, Creighton CJ, Gunaratne PH, Hawkins SM and Matzuk MM: Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. Biol Reprod. 91:1132014. View Article : Google Scholar : PubMed/NCBI | |
|
Merritt MA, Parsons PG, Newton TR, Martyn AC, Webb PM, Green AC, Papadimos DJ and Boyle GM: Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer. 9:3782009. View Article : Google Scholar : PubMed/NCBI | |
|
Newton TR, Parsons PG, Lincoln DJ, Cummings MC, Wyld DK, Webb PM, Green AC and Boyle GM: Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. Int J Cancer. 119:875–883. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, et al: Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res. 14:1900–1910. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, et al: Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 231:21–34. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jannesari-Ladani F, Hossein G and Izadi-Mood N: Differential Wnt11 expression related to Wnt5a in high- and low-grade serous ovarian cancer: Implications for migration, adhesion and survival. Asian Pac J Cancer Prev. 15:1489–1495. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Q, Chen L, Yin X, Liu YJ, Ji Q and Zhao E: Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res. 20:931–938. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD and Drapkin R: Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74:1141–1152. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martins FC, Santiago Id, Trinh A, Xian J, Guo A, Sayal K, Jimenez-Linan M, Deen S, Driver K, Mack M, et al: Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 15:5262014. View Article : Google Scholar : PubMed/NCBI | |
|
Tashiro H, Miyazaki K, Okamura H, Iwai A and Fukumoto M: c-myc over-expression in human primary ovarian tumours: Its relevance to tumour progression. Int J Cancer. 50:828–833. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Kannan K, Coarfa C, Rajapakshe K, Hawkins SM, Matzuk MM, Milosavljevic A and Yen L: CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. PLoS Genet. 10:e10042162014. View Article : Google Scholar : PubMed/NCBI | |
|
Schildkraut JM, Iversen ES, Wilsonv MA, Clyde MA, Moorman PG, Palmieri RT, Whitaker R, Bentley RC, Marks JR and Berchuck A: Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One. 5:e100612010. View Article : Google Scholar : PubMed/NCBI | |
|
Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC and Schlaepfer DD: Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol. 134:104–111. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM and Squire JA: A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 112:1215–1222. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, et al: A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 20:711–723. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Gong G, Tan H, Dai F, Zhu X, Chen Y, Wang J, Liu Y, Chen P, Wu X and Wen J: Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 33:2915–2923. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Li L, Li Z, Gong G, Chen P, Liu H, Wang J, Liu Y and Wu X: The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. Gynecol Oncol. 137:125–133. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Swiercz A, Dansonka-Mieszkowska A, Goryca K, Kulinczak M, Zajdel M, Chechlinska M, Rembiszewska A, Kupryjańczyk J and Siwicki KJ: 273 MiR-7 Expression depends on TP53 mutational status in primary serous ovarian cancer. Eur J Cancer. 48 Suppl 5:S66–S67. 2012. View Article : Google Scholar | |
|
Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, et al: Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer. J Pathol. 226:746–755. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jang SG, Yoo CW, Park SY, Kang S and Kim HK: Low expression of miR-449 in gynecologic clear cell carcinoma. Int J Gynecol Cancer. 24:1558–1563. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, Marsh DJ and Howell VM: Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 12:6272012. View Article : Google Scholar : PubMed/NCBI | |
|
Chong GO, Jeon HS, Han HS, Son JW, Lee YH, Hong DG, Lee YS and Cho YL: Differential microRNA expression profiles in primary and recurrent epithelial ovarian cancer. Anticancer Res. 35:2611–2617. 2015.PubMed/NCBI | |
|
Zhang P, Wang M, Jie ZH, Shuang T, Yan XY, Zhou YY and Wu JL: Detection and significance of miR-210 in chemotherapy resistant and chemotherapy sensitive ovarian serous carcinoma. J China Med Univ. 43:487–492. 2014. | |
|
Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, Goldman M, Barber GP, Clawson H, Coelho A, et al: The UCSC genome browser database: Update 2011. Nucleic Acids Res. 39:(Database Issue). D876–D882. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chekmenev DS, Haid C and Kel AE: P-Match: Transcription factor binding site search by combining patterns and weight matrices. Nucleic Acids Res. 33:W432–W437. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wingender E, Dietze P, Karas H and Knüppel R: TRANSFAC: A database on transcription factors and their DNA binding sites. Nucleic Acids Res. 24:238–241. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P and Olivier M: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene. 26:2157–2165. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM and Anderson ML: Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70:1906–1915. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ibrahim FF, Jamal R, Syafruddin SE, Mutalib Ab NS, Saidin S, MdZin RR, Mollah Hossain MM and Mokhtar NM: microRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer. J Ovarian Res. 8:562015. View Article : Google Scholar : PubMed/NCBI | |
|
Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, et al: miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 17:246–254. 2010. View Article : Google Scholar : PubMed/NCBI |
